Actilyse - referral
Current status
Referral
Human
On 30 September 2002, the European Commission issued a Decision valid throughout the European Union for the medicinal product Actilyse, which contains alteplase. This decision was based on the arbitration assessment report and on the favourable opinion adopted by the Committee for Proprietary Medicinal Products (CPMP) on 27 June 2002. The Marketing Authorisation Holder responsible for this medicinal product is Boehringer Ingelheim Pharma KG.
The new approved indication subject of arbitration is “for fibrinolytic treatment of acute ischemic stroke”.
Between 12 September and 14 September 2000 Boehringer Ingelheim Pharma KG, submitted applications for Mutual Recognition of the Marketing Authorisation granted on 21 August 1999 by the German Competent Authorities, acting as Reference Member State, for Actilyse, powder and solvent for solution for injection and infusion. The Mutual Recognition procedure started on 23 September 2000. The Concerned Member States were Austria, Belgium, Denmark, Greece, Spain, Finland, Ireland, Italy, Luxemburg, France, the Netherlands, Portugal, Sweden and the United Kingdom. The Concerned Member States; the Netherlands, Spain, Greece and the United Kingdom, not being able to agree with the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State referred the reasons for disagreement to the EMEA on 22 December 2000.
The main points to be considered by the CPMP were:
The Reference Member State sent its report to the EMEA on 10 January 2001. The matter was referred to the CPMP on 25 January 2001. The Marketing Authorisation Holder provided supplementary information on 9 August 2001. Written explanations were provided by the Marketing Authorisation Holder on 22 March 2002 and on 29 May 2002. Additional written explanations were provided on 20 June 2002. The Marketing Authorisation Holder provided oral explanations at a hearing before a CPMP Ad Hoc expert group on 22 April 2002 and at hearings before the CPMP plenary on 20 February 2002 and 23 April 2002.
An overall summary of the scientific evaluation is provided, together with the amended Summary of Product Characteristics (SPC) of the Reference Member State (see Annex I).
This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health.
Description of documents published
Please note that some of the listed documents apply only to certain procedures.
Note that older documents may have different titles.